Cardiovascular Revascularization Medicine
Volume 10, Issue 1 , Pages 58-59 , January 2009

Bare metal stent thrombosis 13 years after implantation

Received 17 April 2008 ,Accepted 21 April 2008.

References 

  1. Bavry AA, Kumbhani DJ, Helton TJ, Borek PP, Mood GR, Bhatt DL. Late thrombosis of drug-eluting stents: a meta-analysis of randomized clinical trials. Am J Med. 2006;119:1056–1061
  2. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. Am Heart J. 2006;151:1260–1264
  3. Bertrand OF, Rodes-Cabau J, Poirier P. Very late in-stent restenosis (five years) presenting as an ST elevation acute myocardial infarction. Can J Cardiol. 2004;20:1481–1483
  4. Ferrari E, Benhamou M, Cerboni P, Marcel B. Coronary syndromes following aspirin withdrawal: a special risk for late stent thrombosis. J Am Coll Cardiol. 2005;45:456–459
  5. Kuchulakanti PK, Chu WW, Torguson R, Ohlmann P, Rha SW, Clavijo LC, et al. Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation. 2006;113:1108–1113

☆ Disclosures: Dr. Bhatt discloses the following relationships: Research Grants (directly to the institution) - Bristol Myers Squibb, Eisai, Ethicon, Sanofi Aventis, The Medicines Company; Honoraria (currently donated to non-profits) – Astra Zeneca, Bristol Myers Squibb, Centocor, Daiichi- Sankyo, Eisai, Eli Lilly, Glaxo Smith Kline, Millennium, Paringenix, PDL, Sanofi Aventis, Schering Plough, The Medicines Company, tns Healthcare; Speaker’s bureau (not current, over 2 years ago) – Bristol Myers Squibb, Sanofi Aventis, The Medicines Company; Consultant/Advisory Board (currently donated to non-profits) – Astra Zeneca, Bristol Myers Squibb, Cardax, Centocor, Cogentus, Daiichi-Sankyo, Eisai, Eli Lilly, Glaxo Smith Kline, Johnson & Johnson, McNeil, Medtronic, Millennium, Otsuka, Paringenix, PDL, Philips, Portola, Sanofi Aventis, Schering Plough, The Medicines Company, tns Healthcare, Vertex; Expert testimony regarding clopidogrel (the compensation was donated to a non-profit organization); Cleveland Clinic Coordinating Center currently receives or has received research funding from: Abraxis, Alexion Pharma, AstraZeneca, Atherogenics, Aventis, Biosense Webster, Biosite, Boehringer Ingelheim, Boston Scientific, Bristol-Myers Squibb, Cardionet, Centocor, Converge Medical Inc., Cordis, Dr. Reddy’s, Edwards Lifesciences, Esperion, GE Medical, Genentech, Gilford, GSK, Guidant, J&J, Kensey-Nash, Lilly, Medtronic, Merck, Mytogen, Novartis, Novo Nordisk, Orphan Therapeutics, P&G Pharma, Pfizer, Roche, Sankyo, Sanofi-Aventis, Schering-Plough, Scios, St. Jude Medical, Takeda, TMC, VasoGenix, Viacor. Dr. Bavry discloses the following: honoraria for consulting from The Frankel Group, Boston Scientific, Propagate Pharma, HRA, Marketing Research Services of Houston, Medical Marketing Conference, Hagen/Sinclair Research Recruiting, and KCI Partners.

PII: S1553-8389(08)00207-8

doi: 10.1016/j.carrev.2008.04.003

Cardiovascular Revascularization Medicine
Volume 10, Issue 1 , Pages 58-59 , January 2009

Article Tools

* Image Usage & Resolution